-
公开(公告)号：EP1444224B1
公开(公告)日：2006-05-03
申请号：EP02748081.3
申请日：2002-08-06
发明人： BASTIAN, Jolie, Anne , FINLEY, Don, Richard , HE, John, Xiaoqiang , JESUDASON, Cynthia, Darshini , RATZ, Andrew, Michael , ROCCO, Vincent, Patrick , RUEHTER, Gerd, Lilly Research Laboratories Hamburg , SALL, Daniel, Jon , SCHOTTEN, Theo, Lilly Research Labs. Hamburg , SPINAZZE, Patrick, Gianpietro , STEVENS, Freddie, Craig , TRANKLE, William, George , WERNER, John, Arnold
IPC分类号： C07D403/12 , A61K31/404 , A61P3/04 , C07D409/14 , C07D401/14 , C07D409/12 , C07D405/12 , C07D209/34 , C07D403/14 , C07D417/14
CPC分类号： C07D231/12 , C07D209/34 , C07D233/56 , C07D249/08 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/14
摘要： The present invention relates to a β3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
-
公开(公告)号：EP1303509A1
公开(公告)日：2003-04-23
申请号：EP01952125.1
申请日：2001-07-09
发明人： EVERS, Britta , JESUDASON, Cynthia, Darshini , KARANJAWALA, Rushad, Eruch , REMICK, David, Michael , RUEHTER, Gerd , SALL, Daniel, Jon , SCHOTTEN, Theo , SIEGEL, Miles, Goodman , STENZEL, Wolfgang , STUCKY, Russell, Dean , WERNER, John, Arnold
IPC分类号： C07D409/12 , C07D401/12 , C07D413/12 , C07D213/82 , C07D405/12 , C07D407/12 , C07D409/14 , C07D417/12 , A61K31/44
CPC分类号： C07D207/333 , A61K9/0014 , A61K9/0019 , A61K9/0031 , A61K9/0043 , A61K9/0056 , A61K9/0073 , A61K9/0095 , A61K9/02 , A61K9/08 , A61K9/10 , A61K9/107 , A61K9/12 , A61K9/2054 , C07D213/30 , C07D213/82 , C07D213/84 , C07D261/08 , C07D277/24 , C07D333/16 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The present invention relates to a β3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.
摘要翻译： 本发明涉及式（I）的β3肾上腺素能受体激动剂或其药用盐; 其能够增加细胞中的脂肪分解和能量消耗，因此可用于治疗II型糖尿病和/或肥胖症。 该化合物还可用于降低甘油三酯水平和胆固醇水平，或提高高密度脂蛋白水平或降低肠道蠕动。 此外，该化合物可用于减少神经源性炎症或作为抗抑郁药。 还公开了使用这些化合物治疗糖尿病和肥胖以及降低甘油三酯水平和胆固醇水平或提高高密度脂蛋白水平或降低肠道蠕动的组合物和方法。
-
公开(公告)号：EP1001767A1
公开(公告)日：2000-05-24
申请号：EP98925132.7
申请日：1998-06-01
发明人： DUNLAP, Steven, Eugene , JUNGHEIM, Louis, Nickolaus , TEBBE, Mark, Joseph , VOY, Gilbert, Thomas , WERNER, John, Arnold
IPC分类号： A61K31/415 , C07D235/30
CPC分类号： C07D235/30
摘要： The present application provides a series of benzimidazole compounds of formula (I), which inhibit the growth of picornaviruses, such as rhinoviruses (bovine and human), enteroviruses such as polioviruses, coxsackieviruses of the A and B groups, or echo virus, cardioviruses such as encephalomyocarditis (EMC), apthoviruses such as foot and mouth disease virus, and flaviviruses such as hepatitis C virus and bovine viral diarrhea virus. Such compounds are also useful as intermediates for preparing additional benzimidazole antiviral compounds.
-
公开(公告)号：EP1303509B1
公开(公告)日：2012-11-28
申请号：EP01952125.1
申请日：2001-07-09
发明人： EVERS, Britta , JESUDASON, Cynthia, Darshini , KARANJAWALA, Rushad, Eruch , REMICK, David, Michael , RUEHTER, Gerd , SALL, Daniel, Jon , SCHOTTEN, Theo , SIEGEL, Miles, Goodman , STENZEL, Wolfgang , STUCKY, Russell, Dean , WERNER, John, Arnold
IPC分类号： C07D409/12 , C07D401/12 , C07D413/12 , C07D213/82 , C07D405/12 , C07D407/12 , C07D409/14 , C07D417/12 , A61K31/44 , C07D333/00 , C07D213/00 , C07D303/00 , C07D231/00
CPC分类号： C07D207/333 , A61K9/0014 , A61K9/0019 , A61K9/0031 , A61K9/0043 , A61K9/0056 , A61K9/0073 , A61K9/0095 , A61K9/02 , A61K9/08 , A61K9/10 , A61K9/107 , A61K9/12 , A61K9/2054 , C07D213/30 , C07D213/82 , C07D213/84 , C07D261/08 , C07D277/24 , C07D333/16 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
-
5.发明授权INDOLE DERIVATIVES AS BETA-3 ADRENERGIC AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES 有权吲哚衍生物ASβ-3肾上腺素能激动剂用于治疗2型糖尿病
公开(公告)号：EP1421078B1
公开(公告)日：2006-09-27
申请号：EP02752178.0
申请日：2002-08-06
发明人： BASTIAN, Jolie, Anne , EVERS, Britta Lilly Research Laboratories Hamburg , FINLEY, Don, Richard , HE, John, Xiaoqiang , JESUDASON, Cynthia, Darshini , KARANJAWALA, Rushad, E. , RATZ, Andrew, Michael , ROCCO, Vincent, Patrick , RUEHTER, Gerd Lilly Research Laboratories Hamburg , SALL, Daniel, Jon , SCHOTTEN, Theo Lilly Research Laboratories Hamburg , SPINAZZE, Patrick, Gianpietro , STEVENS, Freddie, Craig , TRANKLE, William, George , WERNER, John, Arnold
IPC分类号： C07D403/12 , C07D409/12 , C07D413/12 , C07D409/14 , C07D417/12 , A61P3/04 , A61P3/10 , A61K31/41 , A61K31/38
CPC分类号： C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要： The present invention relates to a β3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity.
-
公开(公告)号：EP1421078A1
公开(公告)日：2004-05-26
申请号：EP02752178.0
申请日：2002-08-06
发明人： BASTIAN, Jolie, Anne , EVERS, BrittaLilly Research Laboratories Hamburg , FINLEY, Don, Richard , HE, John, Xiaoqiang , JESUDASON, Cynthia, Darshini , KARANJAWALA, Rushad, E. , RATZ, Andrew, Michael , ROCCO, Vincent, Patrick , RUEHTER, GerdLilly Research Laboratories Hamburg , SALL, Daniel, Jon , SCHOTTEN, TheoLilly Research Laboratories Hamburg , SPINAZZE, Patrick, Gianpietro , STEVENS, Freddie, Craig , TRANKLE, William, George , WERNER, John, Arnold
IPC分类号： C07D403/12 , C07D409/12 , C07D413/12 , C07D409/14 , C07D417/12 , A61P3/04 , A61P3/10 , A61K31/41 , A61K31/38
CPC分类号： C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要： The present invention relates to a β3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity.
-
公开(公告)号：EP1341759A2
公开(公告)日：2003-09-10
申请号：EP01985160.9
申请日：2001-10-26
发明人： JESUDASON, Cynthia, Darshini , SALL, Daniel, Jon , STEVENS, Freddie, Craig , WERNER, John, Arnold
IPC分类号： C07D209/34
CPC分类号： C07D401/12 , C07D209/34 , C07D209/96 , C07D403/12 , C07D405/04 , C07D405/12
摘要： The present invention relates to a β;3 adrenergic receptor agonist of formula I: (I);or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity.
-
公开(公告)号：EP1341759B1
公开(公告)日：2006-06-14
申请号：EP01985160.9
申请日：2001-10-26
发明人： JESUDASON, Cynthia, Darshini , SALL, Daniel, Jon , STEVENS, Freddie, Craig , WERNER, John, Arnold
IPC分类号： C07D209/34
CPC分类号： C07D401/12 , C07D209/34 , C07D209/96 , C07D403/12 , C07D405/04 , C07D405/12
摘要： The present invention relates to a β;3 adrenergic receptor agonist of formula I: (I);or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity.
-
公开(公告)号：EP1444224A2
公开(公告)日：2004-08-11
申请号：EP02748081.3
申请日：2002-08-06
发明人： BASTIAN, Jolie, Anne , FINLEY, Don, Richard , HE, John, Xiaoqiang , JESUDASON, Cynthia, Darshini , RATZ, Andrew, Michael , ROCCO, Vincent, Patrick , RUEHTER, Gerd,Lilly Research Laboratories Hamburg , SALL, Daniel, Jon , SCHOTTEN, Theo,Lilly Research Labs. Hamburg , SPINAZZE, Patrick, Gianpietro , STEVENS, Freddie, Craig , TRANKLE, William, George , WERNER, John, Arnold
IPC分类号： C07D403/12 , A61K31/404 , A61P3/04 , C07D409/14 , C07D401/14 , C07D409/12 , C07D405/12 , C07D209/34 , C07D403/14 , C07D417/14
CPC分类号： C07D231/12 , C07D209/34 , C07D233/56 , C07D249/08 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/14
摘要： The present invention relates to a β3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
-
公开(公告)号：EP1054859A1
公开(公告)日：2000-11-29
申请号：EP99903432.5
申请日：1999-01-27
发明人： BARNETT, Charles, Jackson , DUNLAP, Steven, Eugene , KOBIERSKI, Michael, Edward , WERNER, John, Arnold
IPC分类号： C07C255/00 , C07D207/02 , C07D211/04 , C07D213/02 , C07D231/02 , C07D231/04 , C07D231/06 , C07D231/10 , C07D233/02 , C07D233/04 , C07D233/54
CPC分类号： C07D471/04 , C07D333/38 , Y02P20/55
摘要： The present invention concerns intermediates, and processes directed to and from those intermediates, to a series of pyrimidine derivatives of formula (V), which are intermediates to useful antifolate compounds or are themselves useful antifolate compounds.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.016 秒)
